Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Jul 01, 2019

PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics

- Collaboration expands PTC's Gene Therapy portfolio to rare ophthalmic diseases - SOUTH PLAINFIELD, N.J. and BOSTON , July 1, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics today announced a strategic collaboration to develop novel gene therapies in rare

Jun 28, 2019

PTC Provides Update on Translarna™ (ataluren) Application for Label Expansion

SOUTH PLAINFIELD, N.J. , June 28, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has completed their review of a proposed indication extension of Translarna™ (ataluren)

Jun 07, 2019

PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

-- Emflaza is the only approved treatment for all patients two and over living with Duchenne muscular dystrophy -- SOUTH PLAINFIELD, N.J. , June 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration ( FDA ) approved the company's

Jun 03, 2019

PTC Therapeutics Promotes Emily Hill to Chief Financial Officer

SOUTH PLAINFIELD, N.J. , June 3, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in November 2013 and was most recently Senior Vice President and Head of Investor Relations.

May 31, 2019

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , May 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 20, 2019 it approved non-statutory stock options to purchase an aggregate of 76,250 shares of its common stock to 15 new employees. The awards were made pursuant to the NASDAQ

May 30, 2019

PTC Therapeutics to Participate at Upcoming Investor Conference

SOUTH PLAINFIELD, N.J. , May 30, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, June 6th at 4:00 p.m. ET . The presentation will be webcast live on the Events and

May 20, 2019

PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders

- $545,000 awarded to help improve Duchenne muscular dystrophy diagnosis and screening across the globe - SOUTH PLAINFIELD, N.J. , May 20, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three funding recipients from PRIORITY, an annual program to support outstanding

May 09, 2019

PTC Therapeutics and MRI Interventions Announce Strategic Investment

- $4 million equity investment to advance delivery device R&D for CNS gene therapy portfolio and other company operations - SOUTH PLAINFIELD, N.J. and IRVINE, Calif. , May 9, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) and MRI Interventions, Inc.

May 08, 2019

PTC Therapeutics to Participate at Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J. , May 8, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Bank of America Merrill Lynch Healthcare Conference Tuesday, May 14 th at 1:40 p.m.

May 07, 2019

Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients

Babies with Type 1 SMA from Part 1 of FIREFISH continue to achieve motor milestones including standing 58% of patients experienced an improvement of at least 3 points on MFM32 scale vs. baseline after 12 months of treatment in Part 1 of SUNFISH No drug related safety findings leading to withdrawal

Pagination

First page
Previous page
…
Page 25
Page 26
Current page 27
Page 28
Page 29
…
Next page
Last page